Skip to content
Home/Companies/MedTech/Rarecells
Rarecells

Rarecells

MedTech·France·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Rarecells?

Rarecells is a French MedTech company, currently owned by Yaday since 2020.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Yaday
Investor
Yaday
AA Sons Legacy · 2016 · VC

Key facts

HQFrance
SectorMedTech
Websitewww.rarecells.com

More from AA Sons Legacy

Other portfolio companies in the same fund.

Stage11
Stage11
Active
GamingFrance· 2022
Aeler
Aeler
Active
LogisticsSwitzerland· 2021
AnnaBella
AnnaBella
Active
ConsumerFrance· 2021
BodyVision Medical
BodyVision Medical
Active
HealthcareIsrael· 2021
Bruvi
Bruvi
Active
ConsumerUS· 2021
Cashbee
Cashbee
Active
FintechFrance· 2021

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Rarecells?

Rarecells is currently owned by Yaday, through AA Sons Legacy, since 2020.

When did Yaday acquire Rarecells?

Yaday acquired Rarecells in 2020.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue